{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:33:10Z","timestamp":1785198790353,"version":"3.55.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1009958","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/2015\/001276"],"award-info":[{"award-number":["EMR\/2015\/001276"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Biotechnology (DBT), India","award":["BT\/PR5066\/MED\/1582\/2012"],"award-info":[{"award-number":["BT\/PR5066\/MED\/1582\/2012"]}]},{"name":"DBT\/Wellcome Trust India Alliance Early Career Fellowship grant","award":["IA\/E\/18\/1\/504307"],"award-info":[{"award-number":["IA\/E\/18\/1\/504307"]}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. In recent years, highly potent and\/or broadly neutralizing human monoclonal antibodies (bnAbs) that are generated in chronic HIV-1 infections have been defined. These bnAbs exhibit atypical features such as extensive somatic hypermutations, long complementary determining region (CDR) lengths, tyrosine sulfation and presence of insertions\/deletions, enabling them to effectively neutralize diverse HIV-1 viruses despite extensive variations within the core epitopes they recognize. As some of the HIV-1 bnAbs have evolved to recognize the dense viral glycans and cross-reactive epitopes (CREs), we assessed if these bnAbs cross-react with SARS-CoV-2. Several HIV-1 bnAbs showed cross-reactivity with SARS-CoV-2 while one HIV-1 CD4 binding site bnAb, N6, neutralized SARS-CoV-2. Furthermore, neutralizing plasma antibodies of chronically HIV-1 infected children showed cross neutralizing activity against SARS-CoV-2 pseudoviruses. Collectively, our observations suggest that human monoclonal antibodies tolerating extensive epitope variability can be leveraged to neutralize pathogens with related antigenic profile.<\/jats:p>","DOI":"10.1371\/journal.ppat.1009958","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T14:06:47Z","timestamp":1632492407000},"page":"e1009958","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-0486","authenticated-orcid":true,"given":"Nitesh","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-3999","authenticated-orcid":true,"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-1327","authenticated-orcid":true,"given":"Swarandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanu","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-0281","authenticated-orcid":true,"given":"Nishkarsh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-4893","authenticated-orcid":true,"given":"Sumedha","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-8460","authenticated-orcid":true,"given":"Sankar","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-7252","authenticated-orcid":true,"given":"Jayanth Kumar","family":"Palanichamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-2867","authenticated-orcid":true,"given":"Kalpana","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ppat.1009958.ref001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u201csuper-antibodies\u201d enter the fray","volume":"18","author":"LM Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"ppat.1009958.ref002","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure","volume":"48","author":"PD Kwong","year":"2018","journal-title":"Immunity"},{"key":"ppat.1009958.ref003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"D Sok","year":"2018","journal-title":"Nat Immunol"},{"key":"ppat.1009958.ref004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QAI.0000000000000854","article-title":"V1\/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1","volume":"71","author":"M Morgand","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ppat.1009958.ref005","doi-asserted-by":"crossref","first-page":"108693","DOI":"10.1016\/j.vetmic.2020.108693","article-title":"Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses","volume":"244","author":"N Decaro","year":"2020","journal-title":"Vet Microbiol"},{"key":"ppat.1009958.ref006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ppat.1009958.ref007","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"D Wrapp","year":"2020","journal-title":"Science"},{"key":"ppat.1009958.ref008","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"A Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ppat.1009958.ref009","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Y Watanabe","year":"2020","journal-title":"Science"},{"key":"ppat.1009958.ref010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"D Pinto","year":"2020","journal-title":"Nature"},{"key":"ppat.1009958.ref011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.immuni.2018.02.013","article-title":"A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope","volume":"48","author":"T Zhou","year":"2018","journal-title":"Immunity"},{"key":"ppat.1009958.ref012","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nsmb.3291","article-title":"Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site","volume":"23","author":"HB Gristick","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"ppat.1009958.ref013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.celrep.2018.09.087","article-title":"Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth","volume":"25","author":"K Wagh","year":"2018","journal-title":"Cell Rep"},{"key":"ppat.1009958.ref014","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.str.2020.04.022","article-title":"Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions","volume":"28","author":"GE Seabright","year":"2020","journal-title":"Structure"},{"key":"ppat.1009958.ref015","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"J ter Meulen","year":"2006","journal-title":"PLoS Med"},{"key":"ppat.1009958.ref016","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"key":"ppat.1009958.ref017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"J Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"ppat.1009958.ref018","doi-asserted-by":"crossref","first-page":"E513","DOI":"10.3390\/v12050513","article-title":"Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays","volume":"12","author":"KHD Crawford","year":"2020","journal-title":"Viruses"},{"key":"ppat.1009958.ref019","doi-asserted-by":"crossref","first-page":"e20201181","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"F Schmidt","year":"2020","journal-title":"J Exp Med"},{"key":"ppat.1009958.ref020","doi-asserted-by":"crossref","first-page":"e01062","DOI":"10.1128\/JVI.01062-20","article-title":"Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein","volume":"94","author":"MC Johnson","year":"2020","journal-title":"J Virol"},{"key":"ppat.1009958.ref021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"S Xia","year":"2020","journal-title":"Cell Res"},{"key":"ppat.1009958.ref022","doi-asserted-by":"crossref","first-page":"e00515","DOI":"10.1128\/mBio.00515-12","article-title":"Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines","volume":"3","author":"MA M\u00fcller","year":"2012","journal-title":"mBio"},{"key":"ppat.1009958.ref023","doi-asserted-by":"crossref","first-page":"e76469","DOI":"10.1371\/journal.pone.0076469","article-title":"Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation","volume":"8","author":"Z Qian","year":"2013","journal-title":"PLoS One"},{"key":"ppat.1009958.ref024","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1080\/22221751.2020.1815589","article-title":"Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells","volume":"9","author":"H-L Xiong","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"ppat.1009958.ref025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","article-title":"Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2","volume":"28","author":"JB Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ppat.1009958.ref026","doi-asserted-by":"crossref","first-page":"12814","DOI":"10.1074\/jbc.AC120.014918","article-title":"Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a na\u00efve semisynthetic library","volume":"295","author":"HA Parray","year":"2020","journal-title":"J Biol Chem"},{"key":"ppat.1009958.ref027","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1099\/jgv.0.000824","article-title":"Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-na\u00efve children from India","volume":"98","author":"MA Makhdoomi","year":"2017","journal-title":"J Gen Virol"},{"key":"ppat.1009958.ref028","article-title":"An HIV-1 broadly neutralizing antibody from a clade C infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses","author":"S Kumar","year":"2018","journal-title":"J Virol"},{"key":"ppat.1009958.ref029","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00654-19","article-title":"Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins","volume":"93","author":"N Mishra","year":"2019","journal-title":"J Virol"},{"key":"ppat.1009958.ref030","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"D Corti","year":"2016","journal-title":"Science"},{"key":"ppat.1009958.ref031","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1510199112","article-title":"Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus","volume":"112","author":"D Corti","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"ppat.1009958.ref032","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMe1915350","article-title":"Monoclonal Antibody Therapy for Ebola Virus Disease","volume":"381","author":"MM Levine","year":"2019","journal-title":"N Engl J Med"},{"key":"ppat.1009958.ref033","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies","volume":"182","author":"CO Barnes","year":"2020","journal-title":"Cell"},{"key":"ppat.1009958.ref034","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"L Liu","year":"2020","journal-title":"Nature"},{"key":"ppat.1009958.ref035","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"C Wang","year":"2020","journal-title":"Nat Commun"},{"key":"ppat.1009958.ref036","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"SJ Zost","year":"2020","journal-title":"Nature"},{"key":"ppat.1009958.ref037","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"TF Rogers","year":"2020","journal-title":"Science"},{"key":"ppat.1009958.ref038","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/COH.0000000000000049","article-title":"Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination","volume":"9","author":"L Verkoczy","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"ppat.1009958.ref039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12977-018-0435-0","article-title":"Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design","volume":"15","author":"J Finney","year":"2018","journal-title":"Retrovirology"},{"key":"ppat.1009958.ref040","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1172\/JCI125955","article-title":"Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals","volume":"129","author":"J Blazkova","year":"2019","journal-title":"J Clin Invest"},{"key":"ppat.1009958.ref041","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"BF Haynes","year":"2005","journal-title":"Science"},{"key":"ppat.1009958.ref042","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/JVI.02378-14","article-title":"Polyreactivity and autoreactivity among HIV-1 antibodies","volume":"89","author":"M Liu","year":"2015","journal-title":"J Virol"},{"key":"ppat.1009958.ref043","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.celrep.2018.04.101","article-title":"Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity","volume":"23","author":"J Prigent","year":"2018","journal-title":"Cell Rep"},{"key":"ppat.1009958.ref044","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature\u2019s pathways","volume":"254","author":"JR Mascola","year":"2013","journal-title":"Immunol Rev"},{"key":"ppat.1009958.ref045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2016.09.011","article-title":"Neutralization resistant HIV-1 primary isolates from antiretroviral na\u00efve chronically infected children in India","volume":"499","author":"MA Makhdoomi","year":"2016","journal-title":"Virology"},{"key":"ppat.1009958.ref046","doi-asserted-by":"crossref","first-page":"e01883","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"YZ Cohen","year":"2018","journal-title":"J Virol"},{"key":"ppat.1009958.ref047","article-title":"Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates","author":"JCC Lorenzi","year":"2020","journal-title":"J Virol"},{"key":"ppat.1009958.ref048","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"J Huang","year":"2016","journal-title":"Immunity"},{"key":"ppat.1009958.ref049","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fimmu.2020.00984","article-title":"Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development","volume":"11","author":"DC Malherbe","year":"2020","journal-title":"Front Immunol"},{"key":"ppat.1009958.ref050","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.1500527","article-title":"Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens","volume":"196","author":"AJ Hessell","year":"2016","journal-title":"J Immunol"},{"key":"ppat.1009958.ref051","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01796-17","article-title":"A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques","volume":"92","author":"AT Jones","year":"2018","journal-title":"J Virol"},{"key":"ppat.1009958.ref052","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0381","article-title":"The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen","volume":"10","author":"C Havenar-Daughton","year":"2018","journal-title":"Sci Transl Med"},{"key":"ppat.1009958.ref053","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"JG Jardine","year":"2016","journal-title":"Science"},{"key":"ppat.1009958.ref054","article-title":"Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution","author":"F Zhao","year":"2021","journal-title":"bioRxiv"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1009958","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T10:51:19Z","timestamp":1633603879000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009958"}},"subtitle":[],"editor":[{"given":"Kanta","family":"Subbarao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1009958","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.09.418806","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}